The 2018 edition of the CSCO guidelines describes large B-cell lymphoma with IRF4/MUM1 rearrangement, predominantly in the pharyngeal lymphatic ring and/or cervical lymph nodes, mostly early clinical stage, morphologically resembling FL3B or DLBCL, negative for BCL2 rearrangement, and locally aggressive but aggressive but efficacious.

IRF4 gene disruption is also a subtype of CD30-positive cutaneous T-cell lymphoma, and the literature reports that IRF4 disruption can be atypically positive with a variety of 1 red, 1 green, and 1 yellow atypical positivity signals in addition to the typical positive signals, such as 2F+1G extra signals.

The major chaperone gene for IRF4 fusion is IGH, which this probe can be used to distinguish.